BioMedomics Wins Small Business Research Loan from the North Carolina Biotechnology Center.
BioMedomics, Inc. (RTP, NC) is proud to announce that the company was awarded with a $250,000 loan by the North Carolina Biotechnology Center. The loan will support the development of a low-cost, point-of-care test for hemoglobin variants, Hemoglobin S (HbS) and Hemoglobin F (HbF), to aid in the effective treatment decisions for sickle cell disease (SCD). These new tests will be valuable synergistic additions to BioMedomics' existing Sickle Scan® and alpha-Thal Scan® screening tests which have already received CE Mark approval for SCD and alpha thalassemia.
SCD is one of the most common genetic disorders. In US alone, over 100,000 patients suffer from SCD which is a life threatening anemia focused mostly in the African American community. 50% of these patients undergo constant transfusions with the goal of lowering HbS. 30% of these patients receive chronic Hydroxyurea therapy with the goal of raising the patient’s HbF level. Quantitative levels of HbS or HbF are required to optimally manage these patients. Currently it takes several days to a week for clinicians to get these critical results back from central lab analytics. The loan from the NC Biotechnology Center will assist BioMedomics in developing a POC quantitative test for HbS and HbF based on the company’s proprietary Time-Resolved Diagnostic Platform. When available, these tests will give clinicians immediate results of HbS and HbF which will improve treatment for SCD patients.
To learn more about our products in development, please comment below or contact us at firstname.lastname@example.org. For a list of our existing products, please click here. For the related announcement from North Carolina Biotechnology Center, please click here.